Liraglutide vs Sermorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Liraglutide
Liraglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog with 97% homology to native human GLP-1. FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). It was the first GLP-1 agonist approved specifically for obesity. Liraglutide has a shorter half-life than semaglutide (13 hours vs 7 days), requiring daily rather than weekly dosing.
Full details →Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Side-by-Side Comparison
| Aspect | Liraglutide | Sermorelin |
|---|---|---|
| Dose Range | 600 mcg–3 mg | 100 mcg–300 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 16–52 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Liraglutide binds to the GLP-1 receptor, activating the same pathways as native GLP-1: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. A C-16 fatty acid (palmitic acid) attached to Lys26 via a glutamic acid spacer enables albumin binding, extending the half-life from ~2 minutes (native GLP-1) to ~13 hours. Less potent albumin binding and shorter half-life compared to semaglutide necessitates once-daily dosing. | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. |
| Typical Dosage | For weight management (Saxenda): start at 0.6 mg daily for 1 week. Increase by 0.6 mg weekly until reaching 3.0 mg daily maintenance dose. For type 2 diabetes (Victoza): start at 0.6 mg daily for 1 week, increase to 1.2 mg. May increase to 1.8 mg if additional glycemic control is needed. | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. |
| Administration | Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Administer once daily at any time, independent of meals. Store pens refrigerated before first use; after first use, store at room temperature or refrigerated for up to 30 days. | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. |
| Side Effects | Very common (>10%): nausea (up to 40%), diarrhea, constipation, vomiting, decreased appetite, dyspepsia, abdominal pain. Higher rate of daily GI symptoms compared to weekly GLP-1s due to daily dosing peaks. Common (1-10%): headache, dizziness, fatigue, injection site reactions, increased heart rate. | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. |
| Best For |
Key Differences
Unique to Liraglutide:
Unique to Sermorelin:
Key Studies
Liraglutide
- Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.
Journal of clinical medicine, 2025
- Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
JAMA psychiatry, 2025
- Liraglutide for adults living with obesity.
The Cochrane database of systematic reviews, 2025
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
Ready to Learn More?
Looking for trusted sources?